Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorIlgun, Serkan
dc.contributor.authorSarsenov, Dauren
dc.contributor.authorErdogan, Zeynep
dc.contributor.authorOrdu, Cetin
dc.contributor.authorCelebi, Filiz
dc.contributor.authorPilanci, Kezban Nur
dc.contributor.authorOzmen, Vahit
dc.date.accessioned2019-08-13T12:10:23Z
dc.date.accessioned2019-08-13T15:56:53Z
dc.date.available2019-08-13T12:10:23Z
dc.date.available2019-08-13T15:56:53Z
dc.date.issued2016
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.urihttp://hdl.handle.net/11446/2404
dc.descriptionWOS: 000392785500014en_US
dc.descriptionPubMed ID: 28039703en_US
dc.description.abstractPurpose: The receptor status of breast cancer plays a critical role in clinical practice. During the metastatic process, a change in the biological characteristics of the tumor can be seen. This study aimed to investigate the hormone receptor and HER2 status changes between primary and recurrent breast cancers and their effect on survival. Methods: Eighty-six breast cancer patients with biopsy-proven local recurrences or distant metastases during the follow-up period were included in the study. Patients with metastatic disease at the time of first diagnosis or with history of previous neoadjuvant chemotherapy were excluded. Results: Forty-three of the 86 patients (50%) had changes in at least one of the estrogen receptor (ER), progesterone receptor (PR), or HER2. ER, PR and HER2 discordance rates were 12.7,38.3, and 15.1%, respectively, and PR discordance was significantly higher (p=0.000). Among all molecular subtypes, the triple negative breast cancer (TNBC) subtype showed the least change. When the effect of chemotherapy on receptor change was analyzed, PR discordance was significantly higher in the group who received chemotherapy (p =0.029). Analysis of the hormonotherapy effects on receptor discordance revealed results similar to those of chemotherapy. Only the PR discordance was significantly greater in the group that received hormonotherapy (p=0.000). None of the three receptor discordances or loss of any receptor were related to survival. Primary tumor TNBC subtype and disease-free-interval (DFI) shorter than 5 years were found as independent prognostic factors that negatively affected overall survival (OS). Conclusion: This study showed that during recurrent disease there was 50% discordance in the expression of ER, PR, and HER2. The receptor showing the greatest discordance and influence from the systemic treatment was PR. A significant relationship between receptor discordance and survival could not be demonstrated in our study.en_US
dc.language.isoengen_US
dc.publisherIMPRIMATUR PUBLICATIONSen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbreast canceren_US
dc.subjectdiscordanceen_US
dc.subjectmetastasisen_US
dc.subjectreceptoren_US
dc.titleReceptor discordance rate and its effects on survival in primary and recurrent breast cancer patientsen_US
dc.typearticleen_US
dc.relation.journalJOURNAL OF BUONen_US
dc.departmentDBÜen_US
dc.identifier.issue6en_US
dc.identifier.volume21en_US
dc.identifier.startpage1425en_US
dc.identifier.endpage1432en_US
dc.contributor.authorID0000-0002-4862-2891en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Ilgun, Serkan] Gaziosmanpasa Taksim Training & Res Hosp, Dept Gen Surg, Istanbul, Turkey -- [Sarsenov, Dauren] Istanbul Florence Nightingale Hosp, Dept Gen Surg, Istanbul, Turkey -- [Erdogan, Zeynep] Istanbul Florence Nightingale Hosp, Dept Phys Therapy & Rehabil, Istanbul, Turkey -- [Ordu, Cetin] Istanbul Bilim Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- [Celebi, Filiz] Gayrettepe Florence Nightingale Hosp, Dept Radiol, Istanbul, Turkey -- [Pilanci, Kezban Nur] Haseki Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Ozturk, Alper] Biruni Univ, Fac Med, Dept Gen Surg, Istanbul, Turkey -- [Selamoglu, Derya] Mehmet Akif Ersoy Training & Res Hosp, Dept Gen Surg, Istanbul, Turkey -- [Alco, Gul] Gayrettepe Florence Nightingale Hosp, Dept Radiat Oncol, Istanbul, Turkey -- [Aktepe, Fatma] Istanbul Bilim Univ, Fac Med, Dept Pathol, Istanbul, Turkey -- [Eralp, Yesim] Istanbul Univ, Inst Oncol, Dept Med Oncol, Istanbul, Turkey -- [Tuzlali, Sitki] Tuzlali Private Pathol Lab, Istanbul, Turkey -- [Ozmen, Vahit] Istanbul Univ, Capa Med Fac, Dept Gen Surg, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster